MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$5.40 USD
+0.56 (11.57%)
Updated Jul 24, 2024 03:59 PM ET
After-Market: $5.53 +0.13 (2.41%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
MARKER THERAPEUTICS, INC. [MRKR]
Reports for Purchase
Showing records 21 - 40 ( 55 total )
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
4Q20 - AML Phase II Enrollment Timeline is Critical
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
T-cells Against Targeted and Non- Targeted Antigens May Drive Cancer Responses
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Healthcare-Check Out Our Highlights From 2020 ASCO Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
1Q20: Pivotal AML Trial Remains Delayed. Reducing Price Target to $6.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Consider Reading Vol. 7: Observations From Treatment Responsive Cancer Patients
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
4Q19 The Phase II AML Trial Timeline is Crucial in 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
We Highlight Additional Biotech Companies Attending the 2020 Conference
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Maintain Buy With $8PT Amid Clinical Trial Hold Lift
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T